UK cost-consequence analysis of aripiprazole in schizophrenia: Diabetes and coronary heart disease risk projections (STAR study)

European Archives of Psychiatry and Clinical Neuroscience

Volumn 259, Issue 4, 2009, Pages 239-247

  Barnett, Anthony H ^a   Millar, Helen L ^b   Loze, Jean Yves ^c   L'Italien, Gilbert J ^d,e   Van Baardewijk, Marc ^d   Knapp, Martin ^f  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b NHS TAYSIDE   (United Kingdom)

^c Otsuka Pharmaceuticals France   (France)

^d BRISTOL MYERS SQUIBB   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Aripiprazole; Atypical antipsychotic; Cost effectiveness; Diabetes; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEALTH SERVICE; HEALTH SURVEY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CORONARY DISEASE; COST OF ILLNESS; COSTS AND COST ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HEALTH RESOURCES; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; QUINOLONES; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 67349119802     PISSN: 09401334     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00406-008-0863-2     Document Type: Article

References (47)

1. American Diabetes Association 2004 Consensus development conference on antipsychotic drugs and obesity and diabetes (American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity) Diabetes Care 27 596 601
2. American Diabetes Association 2004 Consensus development conference on antipsychotic drugs and obesity and diabetes (American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity) J Clin Psychiatry 65 267 272
3. L Blonde HJ Kan EM Gutterman GJ L'Italien MS Kim L Hanssens RD McQuade 2008 Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care J Clin Psychiatry 69 741 748
4. J Bobes C Arango P Aranda R Carmena M Garcia-Garcia J Rejas 2007 Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study Schizophr Res 90 162 173 (Pubitemid 46177553)
5. S Brown 1997 Excess mortality of schizophrenia. A meta-analysis Br J Psychiatry 171 502 508 (Pubitemid 27527317)
6. S Brown H Inskip B Barraclough 2000 Causes of the excess mortality of schizophrenia Br J Psychiatry 177 212 217
7. F Cassidy E Ahearn BJ Carroll 1999 Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients Am J Psychiatry 156 1417 1420 (Pubitemid 29416540)
8. WK Chrzanowski RN Marcus A Torbeyns M Nyilas RD McQuade 2006 Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine Psychopharmacology (Berl) 189 259 266
9. P Clarke A Gray R Legood A Briggs R Holman 2003 The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65) Diabet Med 20 442 450 (Pubitemid 36776003)
10. Curtis L, Netten A (2006) Unit costs of health and social care. Personal Social Services Research Unit, Canterbury
11. MA De Hert R van Winkel D Van Eyck L Hanssens M Wampers A Scheen J Peuskens 2006 Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication Schizophr Res 83 87 93
12. F Gianfrancesco J Pesa RH Wang H Nasrallah 2006 Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design Am J Health Syst Pharm 63 431 441 (Pubitemid 43334151)
13. DC Goff LM Sullivan JP McEvoy JM Meyer HA Nasrallah GL Daumit S Lamberti RB D'Agostino TS Stroup S Davis JA Lieberman 2005 A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls Schizophr Res 80 45 53 (Pubitemid 41587462)
14. JM Haro L Salvador-Carulla 2006 The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia CNS Drugs 20 293 301
15. CH Hennekens AR Hennekens D Hollar DE Casey 2005 Schizophrenia and increased risks of cardiovascular disease Am Heart J 150 1115 1121 (Pubitemid 41773510)
16. F Henriksson CD Agardh C Berne J Bolinder F Lönnqvist P Stenström CG Ostenson B Jönsson 2000 Direct medical costs for patients with type 2 diabetes in Sweden J Intern Med 248 387 396
17. J Holmes E Gear J Bottomley S Gillam M Murphy R Williams 2003 Do people with type 2 diabetes and their carers lose income? (T2ARDIS-4) Health Policy 64 291 296 (Pubitemid 36543016)
18. H Jin JM Meyer DV Jeste 2004 Atypical antipsychotics and glucose dysregulation: a systematic review Schizophr Res 71 195 212 (Pubitemid 39330499)
19. PB Jones TR Barnes L Davies G Dunn H Lloyd KP Hayhurst RM Murray A Markwick SW Lewis 2006 Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the Latest Antipsychotic drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry 63 1079 1087 (Pubitemid 44498387)
20. B Jönsson 2002 Revealing the cost of Type II diabetes in Europe Diabetologia 45 S5 S12
21. C Kelly RG McCreadie 1999 Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland Am J Psychiatry 156 1751 1757 (Pubitemid 29517568)
22. R Kerwin B Millet E Herman CM Banki H Lublin M Pans L Hanssens G L'Italien RD McQuade JN Beuzen 2007 A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study Eur Psychiatry 22 433 443 (Pubitemid 47600616)
23. M Knapp D King K Pugner P Lapuerta 2004 Non-adherence to antipsychotic medication regimens: associations with resource use and costs Br J Psychiatry 184 509 516 (Pubitemid 38725711)
24. M Knapp R Mangalore J Simon 2004 The global costs of schizophrenia Schizophr Bull 30 279 293 (Pubitemid 38828535)
25. GJ L'Italien DE Casey HJ Kan WH Carson RN Marcus 2007 Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo J Clin Psychiatry 68 1510 1516 (Pubitemid 350073397)
26. DL Leslie RA Rosenheck 2005 Pharmacotherapy and health care costs among patients with schizophrenia and newly diagnosed diabetes Psychiatr Serv 56 803 809 (Pubitemid 40967456)
27. JA Lieberman 2004 Dopamine partial agonists: a new class of antipsychotic CNS Drugs 18 251 267 (Pubitemid 38393435)
28. JA Lieberman TS Stroup JP McEvoy MS Swartz RA Rosenheck DO Perkins RS Keefe SM Davis CE Davis BD Lebowitz J Severe JK Hsiao 2005 Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 1209 1223 (Pubitemid 41345943)
29. R Luengo-Fernández J Leal A Gray S Petersen M Rayner 2006 Cost of cardiovascular diseases in the United Kingdom Heart 92 1384 1389 (Pubitemid 44578822)
30. JP McEvoy JM Meyer DC Goff HA Nasrallah SM Davis L Sullivan HY Meltzer J Hsiao T Scott Stroup JA Lieberman 2005 Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III Schizophr Res 80 19 32 (Pubitemid 41587460)
31. RD McQuade E Stock R Marcus D Jody NA Gharbia S Vanveggel D Archibald WH Carson 2004 A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study J Clin Psychiatry 65 Suppl 18 47 56
32. National 2006 CG38 Bipolar disorder NICE
33. National Institute for Clinical Excellence (2002) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. In: Technology appraisal No. 43. London
34. National Institute for Clinical Excellence (2004) Guide to the methods of technology appraisal. In: National Institute for Clinical Excellence, London
35. National Institute of Clinical Excellence (2003) Schizophrenia: full national clinical guideline on core interventions in primary and secondary care. In: National Institute of Clinical Excellence
36. SC Newman RC Bland 1991 Mortality in a cohort of patients with schizophrenia: a record linkage study Can J Psychiatry 36 239 245
37. DP Osborn G Levy I Nazareth I Petersen A Islam MB King 2007 Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database Arch Gen Psychiatry 64 242 249 (Pubitemid 46220782)
38. M Osiri ME Suarez-Almazor GA Wells V Robinson P Tugwell 2003 Number needed to treat (NNT): implication in rheumatology clinical practice Ann Rheum Dis 62 316 321 (Pubitemid 36363436)
39. SG Potkin AR Saha MJ Kujawa WH Carson M Ali E Stock J Stringfellow G Ingenito SR Marder 2003 Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder Arch Gen Psychiatry 60 681 690 (Pubitemid 36818630)
40. Primatesta P (2004) Health survey for England 2003. In: Sproston K, Primatesta P (eds) The Stationary Office, Norwich, UK
41. KL Rascati MT Johnsrud ML Crismon MJ Lage BL Barber 2003 Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid recipients Pharmacoeconomics 21 683 697 (Pubitemid 36920634)
42. R Rosenheck J Cramer E Allan J Erdos LK Frisman W Xu J Thomas W Henderson D Charney 1999 Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia Arch Gen Psychiatry 56 565 572
43. R Rosenheck J Cramer W Xu J Grabowski R Douyon J Thomas W Henderson D Charney 1998 Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia Health Serv Res 33 1237 1261
44. MP Stern K Williams SM Haffner 2002 Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136 575 581 (Pubitemid 34407041)
45. R Tandon RN Marcus EG Stock LC Riera D Kostic M Pans RD McQuade M Nyilas T Iwamoto DT Crandall 2006 A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial with Aripiprazole (BETA) Schizophr Res 84 77 89 (Pubitemid 44255718)
46. PW Wilson RB D'Agostino D Levy AM Belanger H Silbershatz WB Kannel 1998 Prediction of coronary heart disease using risk factor categories Circulation 97 1837 1847 (Pubitemid 28213628)
47. N Zethraeus T Molin P Henriksson B Jönsson 1999 Costs of coronary heart disease and stroke: the case of Sweden J Intern Med 246 151 159 (Pubitemid 29378920)